Standards & Regulation

Our latest roundup reports on Trump's “most favored nation” order, an EMA investigation into finasteride, and Novo Nordisk’s continued R&D for obesity

Trump continues to send shockwaves through the industry. We look at FDA disruption, tariffs, funding volatility, and more.

We speak with an advocate for alternative drug testing methods about the challenges that lie ahead.

Our latest news roundup reports on Novartis’ new acquisition, an NIH grant for an Alzheimer’s disease vaccine, and more

Attorney Generals claim: “This administration is not streamlining the federal government; they are sabotaging it.”

As mental health disorders escalate, pharmaceutical innovators can harness advanced tools to accelerate much-needed treatments.

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

FDA to phase out mandatory animal testing with human-relevant methods for drug development